Antipain
Also known as: [N-alpha-(N-(N-((S)-1-Carboxy-2-phenylethyl)carbamoyl)-arg-val)]-arginal, Ac-Leu-Leu-Arg-CHO, Antipain, Antipain dihydrochloride, Antipain hydrochloride, Leu-Arg-Arg-CHO, Leu-Leu-Arg-al, Protease inhibitor antipain
Source Antipain at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Affiliate link: we earn a commission on purchases made through this link, at no extra cost to you.
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Antipain is a small peptide originally isolated from microorganisms that belongs to the protease‑inhibitor family. It is employed primarily as a research tool to block protease activity in biochemical and cellular assays, and its inhibitory profile has sparked interest in possible analgesic mechanisms. Antipain has not been approved for any therapeutic indication and remains confined to laboratory investigations.
Mechanism of Action
Antipain acts by binding to the active site of proteases, most often serine‑type enzymes, thereby preventing the hydrolysis of peptide substrates. By blocking proteolytic processing of pro‑pain mediators, it can theoretically dampen downstream nociceptive signaling. The inhibition is reversible and depends on the peptide’s affinity for the target protease’s catalytic pocket.
What the Research Shows
The peer‑reviewed literature mentions Antipain in the context of its protease‑inhibitory (antipain) activity. A 2022 review of mustard‑seed glucosinolates lists antipain among the antimicrobial and antipain properties of those natural compounds, highlighting its potential to modulate pain‑related enzymes. A 2010 overview of carbonic anhydrase inhibitors cites Antipain as one of the emerging applications (antipain, anti‑obesity, antitumor) of novel enzyme inhibitors. No clinical trials or human efficacy studies of Antipain itself are reported; its use is confined to in‑vitro and pre‑clinical models as a tool to interrogate protease function.
Reported Benefits
In research settings, Antipain provides a selective means to inhibit proteases, enabling the dissection of protease‑dependent pathways such as inflammation, tissue remodeling, and pain signaling. Its peptide nature allows relatively straightforward synthesis and modification, facilitating structure‑activity studies. Preliminary pre‑clinical observations suggest that protease inhibition by Antipain could attenuate nociceptive processes, offering a conceptual basis for future analgesic exploration.
Limitations of the Evidence
Evidence for Antipain is limited to laboratory studies; there are no animal efficacy data, pharmacokinetic profiles, or safety assessments in humans. Its specificity across the broad protease family is not fully characterized, raising the possibility of off‑target effects. Because it has never progressed beyond the research stage, regulatory status, dosing, and formulation remain undefined, precluding any therapeutic use at present.
Safety Considerations
The published abstracts do not report adverse events associated with Antipain, reflecting its exclusive use in vitro. Consequently, human safety, immunogenicity, or toxicity are unknown. As with many peptide reagents, potential concerns include immune reactions, proteolytic degradation, and unintended inhibition of physiologically important proteases. Caution is advised when extrapolating laboratory findings to clinical contexts.
How It Is Administered
Antipain is administered experimentally by direct addition to cell culture media, assay buffers, or isolated enzyme preparations. It is supplied as a synthetic peptide (often as a dihydrochloride or hydrochloride salt) for laboratory use. No oral, injectable, or topical formulations for patient use have been reported.
Routes of Administration
No administration routes recorded yet.
Goals & Uses
- Investigation of protease roles in cellular processesResearch/pharmacologyModerate
- Inhibition of cathepsin B activityResearch/biochemistryHigh
- Inhibition of trypsin-like serine proteasesResearch/biochemistryHigh
- Protease inhibition in vitroResearch ToolHigh
- Protease inhibition in cell lysatesResearch/biochemistryHigh
Contraindications
No contraindications recorded yet.
Adverse Effects
- Cytotoxicity at high concentrationsIn Vitro ToxicityUncommon
Drug Interactions
No drug interactions recorded yet.
Population Constraints
- Not for human or veterinary therapeutic useGeneralAbsolute
Regulatory Status
- European UnionUnapprovedResearch use only; not EMA approved
- United StatesUnapprovedNot approved for any clinical indication; available only as a research chemical.
- United KingdomUnapprovedResearch use only; not MHRA approved
Not approved for human therapeutic use; classified as a research chemical.
Evidence & Sources
- Journal ArticleModerateMartins YC, et al.2025-01-01T00:00:00.000000Z
- Journal ArticleModerateField T2012-01-01T00:00:00.000000Z
- Journal ArticleModerateGough N, Miah AB, Linch M2014-01-01T00:00:00.000000Z
- Journal ArticleModerateDas G, et al.2022-01-01T00:00:00.000000Z
- Journal ArticleModerateSupuran CT2010-01-01T00:00:00.000000Z
- Journal ArticleModeratePickart L, Margolina A2018-01-01T00:00:00.000000Z
Frequently Asked Questions
Is Antipain an approved drug for pain relief?
No. Antipain is a research‑grade peptide inhibitor and has not received regulatory approval for any therapeutic indication, including analgesia.
What types of proteases does Antipain inhibit?
The literature classifies Antipain as a protease inhibitor, most commonly targeting serine proteases, though detailed isoform specificity has not been fully defined in published studies.
Can Antipain be used in clinical trials?
At present there are no clinical trials involving Antipain; its use is limited to pre‑clinical experiments, and further safety and pharmacology data would be required before human studies could be considered.
How is Antipain typically prepared for experiments?
Researchers obtain Antipain as a synthetic peptide, often supplied as a dihydrochloride or hydrochloride salt, and dissolve it in aqueous buffers for addition to enzymatic or cellular assays.
Does Antipain have any known side effects?
Published abstracts do not describe side effects, reflecting a lack of human exposure data. Potential risks remain speculative and would need formal toxicological evaluation.
What is Antipain?
Antipain is a small peptide originally isolated from microorganisms that belongs to the protease‑inhibitor family. It is employed primarily as a research tool to block protease activity in biochemical and cellular assays, and its inhibitory profile has sparked interest in possible analgesic mechanisms. Antipain has not been approved for any therapeutic indication and remains confined to laboratory investigations.
What is Antipain used for?
Antipain is educationally associated with: Investigation of protease roles in cellular processes, Inhibition of cathepsin B activity, Inhibition of trypsin-like serine proteases, Protease inhibition in vitro, Protease inhibition in cell lysates. Educational only — not medical advice.
What are the potential side effects of Antipain?
Reported adverse effects include: Cytotoxicity at high concentrations. This list is not exhaustive — consult a qualified clinician.